UNICA IRIS Institutional Research Information System

MORELLI, MICAELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 243.793
NA - Nord America 17.969
AS - Asia 5.548
SA - Sud America 1.084
AF - Africa 99
Continente sconosciuto - Info sul continente non disponibili 19
OC - Oceania 12
Totale 268.524
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 239.784
US - Stati Uniti d'America 17.788
CN - Cina 2.481
SG - Singapore 2.146
UA - Ucraina 1.484
BR - Brasile 913
SE - Svezia 829
DE - Germania 495
GB - Regno Unito 418
FI - Finlandia 374
VN - Vietnam 341
KR - Corea 170
FR - Francia 146
CA - Canada 113
IN - India 82
HK - Hong Kong 68
AR - Argentina 60
RU - Federazione Russa 53
MX - Messico 49
JP - Giappone 34
BD - Bangladesh 33
PL - Polonia 32
EC - Ecuador 31
ZA - Sudafrica 30
TR - Turchia 28
IQ - Iraq 27
NL - Olanda 27
BE - Belgio 26
CO - Colombia 26
ID - Indonesia 26
ES - Italia 25
AT - Austria 20
IL - Israele 19
EG - Egitto 17
EU - Europa 17
MA - Marocco 15
PK - Pakistan 14
CZ - Repubblica Ceca 13
CL - Cile 12
IE - Irlanda 12
LT - Lituania 10
PE - Perù 10
AU - Australia 9
KE - Kenya 9
PY - Paraguay 9
UZ - Uzbekistan 9
VE - Venezuela 9
AE - Emirati Arabi Uniti 8
JM - Giamaica 8
RO - Romania 8
SA - Arabia Saudita 8
AZ - Azerbaigian 7
BO - Bolivia 7
NP - Nepal 7
TN - Tunisia 7
UY - Uruguay 7
IR - Iran 6
CH - Svizzera 5
DZ - Algeria 5
JO - Giordania 5
KZ - Kazakistan 5
MU - Mauritius 5
NO - Norvegia 5
AL - Albania 4
ET - Etiopia 4
PT - Portogallo 4
TW - Taiwan 4
BY - Bielorussia 3
DK - Danimarca 3
HR - Croazia 3
MY - Malesia 3
NG - Nigeria 3
BG - Bulgaria 2
CR - Costa Rica 2
GE - Georgia 2
KG - Kirghizistan 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
SV - El Salvador 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BS - Bahamas 1
BW - Botswana 1
CI - Costa d'Avorio 1
CY - Cipro 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GI - Gibilterra 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
KH - Cambogia 1
LB - Libano 1
LK - Sri Lanka 1
ME - Montenegro 1
MN - Mongolia 1
Totale 268.514
Salva come PNG Salva come JPEG
Città #
Cagliari 233.099
Uta 5.888
Fairfield 2.329
Woodbridge 1.633
Ashburn 1.424
Chandler 1.273
Houston 1.100
Singapore 1.038
Seattle 945
Wilmington 917
Ann Arbor 849
Boardman 812
Jacksonville 796
Dallas 790
Cambridge 757
Nyköping 508
Beijing 462
Dearborn 316
Nanjing 271
Los Angeles 241
Hefei 222
New York 219
Boston 200
Santa Clara 169
Seoul 162
Shanghai 145
San Diego 131
Helsinki 130
Buffalo 127
Hangzhou 108
Ho Chi Minh City 99
Shenyang 89
Milan 86
The Dalles 81
Redwood City 78
Hebei 73
São Paulo 72
Dong Ket 70
Toronto 64
Nanchang 63
Hong Kong 62
London 61
Mountain View 58
Munich 58
Redondo Beach 57
Changsha 55
Guangzhou 55
Verona 50
Hanoi 48
Jiaxing 47
Chicago 45
Tianjin 44
Norwalk 43
Jinan 38
Rome 38
Council Bluffs 37
Zhengzhou 35
Washington 33
Brooklyn 31
Sassari 30
Auburn Hills 29
Rio de Janeiro 26
Orange 25
Tokyo 25
Ningbo 23
Brussels 22
Atlanta 20
Belo Horizonte 19
Brasília 19
Falls Church 19
Frankfurt am Main 19
Montreal 19
Phoenix 19
Warsaw 19
Chennai 18
Curitiba 18
Pune 17
Da Nang 15
Indiana 15
Nuremberg 15
Oristano 15
Paris 15
Porto Alegre 15
Columbus 14
Mexico City 14
San Jose 14
Stockholm 14
Kunming 13
Taizhou 13
Wuhan 13
Elk Grove Village 12
Sestu 12
Dublin 11
Haiphong 11
Johannesburg 11
Vienna 11
Denver 10
Guayaquil 10
Redmond 10
Salt Lake City 10
Totale 259.410
Salva come PNG Salva come JPEG
Nome #
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease. 4.291
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease 4.258
Odor identification performance in idiopathic Parkinson’s disease is associated with gender and the genetic variability of the olfactory binding protein 3.629
Pharmacological characterization of 50-kHz ultrasonic vocalizations in rats: comparison of the effects of different psychoactive drugs and relevance in drug-induced reward 3.593
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease 3.517
Role of Adenosine in the basal Ganglia 3.324
Antagonism of Adenosine A1 or A2A Receptors Amplifies the Effects of 3,4-Methylendioxymethamphetamine (MDMA) on Glial Activation in the Mouse Brain: Relevance to Caffeine-MDMA Interactions 3.075
Elevation of striatal urate in experimental models of Parkinson's disease: a compensatory mechanism triggered by dopaminergic nigrostriatal degeneration? 2.966
Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms 2.916
Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists 2.875
Vitamin A deficiency induces motor impairments and striatal cholinergic dysfunction in rats 2.838
Direct and long-lasting effects elicited by repeated drug administration on 50-kHz ultrasonic vocalizations are regulated differently: Implications for the study of the affective properties of drugs of abuse 2.806
Modulation of rat 50-kHz ultrasonic vocalizations by glucocorticoid signaling: possible relevance to reward and motivation 2.786
Role of adenosine A2A receptors in motor control: relevance to Parkinson’s disease and dyskinesia 2.724
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice 2.686
Effect of crowding, temperature and age on glia activation and dopaminergic neurotoxicity induced by MDMA in the mouse brain 2.679
Methylxanthines and drug dependence: interactions and toxicity 2.664
MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA pretreated mice 2.653
Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson’s Disease 2.630
Influence of caffeine on 3,4-methylenedioxymethamphetamine-induced dopaminergic neuron degeneration and neuroinflammation is age-dependent 2.608
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease 2.595
Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility 2.501
Progression and Persistence of Neurotoxicity Induced by MDMA in Dopaminergic Regions of the Mouse Brain and Association with Noradrenergic, GABAergic, and Serotonergic Damage 2.480
Repeated Administration of 3,4-Methylenedioxymethamphetamine (MDMA) Elevates the Levels of Neuronal Nitric Oxide Synthase in the Nigrostriatal System: Possible Relevance to Neurotoxicity 2.475
Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease 2.470
Influence of dopamine transmission in the medial prefrontal cortex and dorsal striatum on the emission of 50-kHz ultrasonic vocalizations in rats treated with amphetamine: Effects on drug-stimulated and conditioned calls 2.464
Lack of Rhes Increases MDMA-Induced Neuroinflammation and Dopamine Neuron Degeneration: Role of Gender and Age 2.432
Involvement of Glutamate NMDA Receptors in the Acute, Long-Term, and Conditioned Effects of Amphetamine on Rat 50kHz Ultrasonic Vocalizations 2.404
Activation of adenosine A2A receptors suppresses the emission of pro-social and drug-stimulated 50-kHz ultrasonic vocalizations in rats: possible relevance to reward and motivation 2.379
Rhes counteracts dopamine neuron degeneration and neuroinflammation depending on gender and age 2.356
The Small GTP-Binding Protein Rhes Influences Nigrostriatal-Dependent Motor Behavior During Aging 2.354
Genetic variants of TAS2R38 bitter taste receptor associate with distinct gut microbiota traits in Parkinson's disease: A pilot study 2.311
null 2.277
A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A2A receptor antagonists 2.275
Gut Microbiota and Metabolome Alterations Associated with Parkinson’s Disease 2.274
MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex 2.226
Contribution of Caffeine to the Psychostimulant, Neuroinflammatory and Neurotoxic Effects of Amphetamine-Related Drugs 2.167
Caffeine Enhances Astroglia and Microglia Reactivity Induced by 3,4-Methylenedioxymethamphetamine (‘Ecstasy’) in Mouse Brain 2.115
Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons 2.073
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression 2.059
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug 2.056
NCX1 and NCX3 as potential factors contributing to neurodegeneration and neuroinflammation in the A53T transgenic mouse model of Parkinson's Disease 1.979
Preface [ to The Adenosinergic System. A Non-Dopaminergic Target in Parkinson’s Disease] 1.959
Repeated amphetamine administration and long-term effects on 50-kHz ultrasonic vocalizations: possible relevance to the motivational and dopamine-stimulating properties of the drug 1.942
Role of movement in long-term basal ganglia changes: implications for abnormal motor responses 1.927
Neurochemical and neurotoxic effects of MDMA (Ecstasy) and caffeine after chronic combined administration in mice 1.926
Metformin prevented dopaminergic neurotoxicity induced by 3,4-Methylenedioxymethamphetamine administration 1.884
Alteration in the progression of dopamine neuron degeneration: May caffeine offer new perspective? 1.843
Neuroinflammation and activation of Zif-268 in dyskinetic 6-OHDA-lesioned rats is counteracted by association of a 5-HT1A/1B receptor agonist and an A2A receptor antagonist 1.798
Farmaci antiparkinsoniani ed attivi in altri disturbi motori 1.793
Gender Differences in Neurodegeneration, Neuroinflammation and Na+-Ca2+ Exchangers in the Female A53T Transgenic Mouse Model of Parkinson’s Disease 1.789
Increased emissions of 50-kHz ultrasonic vocalizations in hemiparkinsonian rats repeatedly treated with dopaminomimetic drugs: A potential preclinical model for studying the affective properties of dopamine replacement therapy in Parkinson's disease 1.773
Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions 1.769
Combined administration of dopaminergic and nondopaminergic drugs reverses neuroinflammation in a rat model of Parkinson’s disease 1.766
Behavioral, neurochemical, and electrophysiological changes in an early spontaneous mouse model of nigrostriatal degeneration 1.761
Caffeine consumption and changes in the function of dopaminergic transmission: evidence of a hyperdopaminergic state in rats subchronically treated with caffeine 1.756
Decreased Rhes mRNA levels in the brain of patients with Parkinson’s disease and MPTP-treated macaques 1.701
Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease. 1.667
null 1.651
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat 1.604
Antiparkinsonian actions and interactions of adenosine antagonists 1.600
The small GTP-binding protein Rhes influences midbrain dopaminergic neurons: Behavioral and biochemical studies 1.542
Farmaci utilizzati nella terapia della Malattia di Parkinson e di altri disturbi motori 1.528
Gender-dependent behavioral and biochemical differences in the A53T genetic mouse model of Parkinson’s disease 1.408
Effect of caffeine on 3,4- methylenedioxymethamphetamine-induced neuroinflammation in mouse brain 1.377
Adenosine signaling in the basal ganglia 1.273
Blockade of globus pallidus adenosine A2A receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D1 or D2 dopamine receptor agonists 1.257
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats 1.253
Effect of caffeine on 3, 4 – methylenedioxymethamphetamine – induced astroglia and microglia activation in mouse brain 1.239
null 1.194
Acute perinatal asphyxia impairs non-spatial memory and alters motor coordination in adult male rats 1.180
The 6-hydroxydopamine model of Parkinson's disease 1.164
Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease 1.138
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence 1.138
Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats 1.133
Adenosine A2A receptor antagonist treatment of Parkinson’s disease 1.125
Adenosine A2A receptor antagonists and Parkinson’s disease: state of the art and future directions 1.110
null 1.108
Function of dopamine in the extrapyramidal and limbic systems 1.090
In utero exposure to dexamethasone causes a persistent and age-dependent exacerbation of the neurotoxic effects and glia activation induced by MDMA in dopaminergic brain regions of C57BL/6J mice 1.082
A2A receptor antagonism and dyskinesia in Parkinson’s Disease 1.071
A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease 1.071
Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties 1.067
Caffeine Consumption and Changes in the Function of Dopaminergic Transmission: Evidence of a Hyperdopaminergic State in Rats Subchronically Treated with Caffeine 1.057
6-n-propylthiouracil taste disruption and TAS2R38 nontasting form in Parkinson's disease 1.044
Adenosine A2A receptors and Parkinson's disease 1.037
null 1.012
Methylxanthines and Drug Dependence: A Focus on Interactions with Substances of Abuse 1.004
Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease 1.004
Anxyiolytic properties of a 2-phenylindolglyoxylamide TSPO ligand: Stimulation of in vitro neurosteroid production affecting GABAA receptor activity 996
null 981
null 967
Changes in the expression of tonic and phasic neurochemical markers of activity in a rat model of L-DOPA induced dyskinesia 948
Differential effect of MK 801 and scopolamine on c-fos expression induced by L-dopa in the striatum of 6-hydroxydopamine lesioned rats 939
Activation of Antioxidant and Proteolytic Pathways in the Nigrostriatal Dopaminergic System After 3,4-Methylenedioxymethamphetamine Administration: Sex-Related Differences 934
Withania somnifera influences MDMA-induced hyperthermic, cognitive, neurotoxic and neuroinflammatory effects in mice 926
Changes in the expression of tonic and phasic neurochemical markers of activity in a rat model of L-DOPA induced dynskinesia 922
Effects of docosanyl ferulate, a constituent of Withania somnifera, on ethanol- and morphine-elicited conditioned place preference and ERK phosphorylation in the accumbens shell of CD1 mice 914
Birth asphyxia as the major complication in newborns: Moving towards improved individual outcomes by prediction, targeted prevention and tailored medical care 912
Protective Agents in Parkinson’s Disease: Caffeine and Adenosine A2A Receptor Antagonists 902
Totale 189.196
Salva come PNG Salva come JPEG
Categoria #
all - tutte 369.137
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 369.137
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202127.875 0 0 0 0 0 7.936 6.522 3.611 1.395 3.401 2.864 2.146
2021/202213.605 1.299 1.202 874 806 878 1.004 1.109 716 832 1.321 1.539 2.025
2022/202321.093 1.985 2.506 1.915 1.779 1.902 2.223 1.052 1.816 1.484 1.548 1.991 892
2023/202424.574 1.019 971 1.077 1.426 2.404 4.033 3.710 1.751 1.002 2.055 2.489 2.637
2024/202537.231 5.784 7.130 6.779 5.143 2.705 3.688 3.579 324 599 466 468 566
2025/20266.577 955 742 1.753 1.447 1.083 597 0 0 0 0 0 0
Totale 269.316